Download Files:
Selatinib
SKU
HY-116437-10 mg
Category Reference compound
Tags Cancer, EGFR, JAK/STAT Signaling;Protein Tyrosine Kinase/RTK
$300 – $2,400
Products Details
Product Description
– Selatinib is a reversible and orally active dual EGFR and ErbB2 inhibitor with IC50s of 13 nM and 22.5 nM, respectively. Selatinib has anticancer effects[1].
Web ID
– HY-116437
Storage Temperature
– 4°C (Powder, protect from light)
Shipping
– Room Temperature
Applications
– Cancer-Kinase/protease
Molecular Formula
– C29H26ClFN4O3S
References
– [1]Meng-Na Wang, et al. First-in-human, phase I single-ascending-dose study of the safety, pharmacokinetics, and relative bioavailability of selatinib, a dual EGFR-ErbB2 inhibitor in healthy subjects. Invest New Drugs. 2020 Dec;38(6):1826-1835.
CAS Number
– 1275595-86-2
Molecular Weight
– 565.06
Compound Purity
– 99.83
SMILES
– O=S(C)CCNCC1=CC=C(O1)C2=CC3=C(N=CN=C3C=C2)NC4=CC=C(C(Cl)=C4)OCC5=CC=CC(F)=C5
Clinical Information
– Phase 1
Research Area
– Cancer
Solubility
– DMSO : 100 mg/mL (ultrasonic)
Target
– EGFR
Isoform
– EGFR/ErbB1/HER1;ErbB2/HER2
Pathway
– JAK/STAT Signaling;Protein Tyrosine Kinase/RTK
Product type
– Reference compound
Disclaimer: All products are for Research use only unless clearly stated otherwise on the product datasheet. Datasheets provided on the website are drafts for reference purpose only and you are requested to always refer to the hard copy included in the kit for your experimentation. Agdia Products are available for delivery only in Canada.